Fundraising FoxIaso Therapeutics
East Lansing, US · Founded 2018 · Delaware corporation · 2 known investors
Find your way into Iaso Therapeutics
Sign up to see every warm intro you have to Iaso Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Iaso Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
IASO Therapeutics develops synthetic antigen vaccines using a mutant Qβ virus-like particle carrier platform to generate targeted, durable immunity. The company focuses on next-generation vaccines for infectious disease prevention, including combating antimicrobial resistance.
Founders & leadership
Board
Investors · 2
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$1M disclosed across 2 rounds · 2022–2026
▶$570KraisedJan 2026 · 1 investors · BiotechnologyRule 506(b)
- Steve KuemmerieDirector
- Robert ForgeyExecutive Officer, Director
- Xuefei HuangExecutive Officer, Director
- Donald ParfetDirector
- Jeffrey WesleyDirector
- Offering amount
- $1.8M
- Amount sold
- $570K
- Minimum investment
- $25K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$437.9KraisedJan 2023 · 5 investors · BiotechnologyRule 506(b)
- Xuefei HuangExecutive Officer, Director
- Herbert KavunjaExecutive Officer
- Jeffrey WesleyDirector
- Donald ParfetDirector
- Robert ForgeyExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $437.9K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Iaso Therapeutics.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2022 | $978.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $594.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $300K |
| National Science Foundation | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Iaso Therapeutics do?
- IASO Therapeutics develops synthetic antigen vaccines using a mutant Qβ virus-like particle carrier platform to generate targeted, durable immunity. The company focuses on next-generation vaccines for infectious disease prevention, including combating antimicrobial resistance.
- Who are Iaso Therapeutics's investors?
- Iaso Therapeutics's investors include Michigan Rise, WMU Biosciences Research & Commercialization Center.
- How much funding has Iaso Therapeutics raised?
- Iaso Therapeutics has disclosed $1M raised across 2 rounds.
- Where is Iaso Therapeutics headquartered?
- Iaso Therapeutics is headquartered in East Lansing, US.